MRNA
$53.93
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Recent News
Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?
The FDA's embattled vaccine chief, Vinay Prasad, will exit the agency. But that doesn't mean biotech stocks should breathe easy.
BioNTech Stock Is a Bargain. Why Its Recent Selloff Is a Buying Opportunity.
The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.
GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger Adults
GSK secures FDA approval to expand Arexvy's use to high-risk adults aged 18-49 years, broadening access as the company pushes wider global adoption.
The S&P 500's 3 Best-Performing Stocks So Far in 2026
Despite a broad market selloff, SNDK, TPL, and MRNA stand out as the S&P 500's 3 best-performing stocks in 2026, each operating in a different sector.
Man's dog was riddled with tumors and dying. He used ChatGPT to design a custom cancer vaccine, stunning researchers
With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are spending billions to bring the same technology to human patients.